posted on Jun, 2 2008 @ 04:01 PM
Phase 2 studies show the experimental vaccine from Avant and Pfizer doubled survival period and delayed progress in some brain cancers patients.
CHICAGO (AP) -- Shares of Avant Immunotherapeutics surged Monday, after the vaccine developer and partner Pfizer Inc. released mid-stage data showing
their vaccine doubled overall survival time, and delayed disease progression in certain brain cancer patients.
The companies presented data from two Phase 2 studies at the American Society of Clinical Oncology's annual meeting in Chicago. CDX-110 is an
experimental vaccine targeting a growth factor specific to tumors in patients with glioblastoma multiforme (GBM), the most common and aggressive form
of brain cancer.
There are an estimated 10,000 new cases of GBM annually in the United States, including Massachusetts Democratic Sen. Edward Kennedy.
[edit on 2-6-2008 by grover]